Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI)

Rhea-AI Summary

Avenue Therapeutics, Inc. (NASDAQ:ATXI) successfully completed a $12 million underwritten public offering, with Aegis Capital Corp. serving as the sole bookrunner on October 12, 2022. The funds raised will support the company's development of intravenous Tramadol, a dual-acting opioid currently in Phase III trials for treating post-operative acute pain. Avenue Therapeutics focuses on specialty pharmaceuticals for acute care settings and was incorporated in 2015.

Positive

• Raised $12 million to support clinical development.
• Funding will advance Phase III trials of intravenous Tramadol.

Negative

• None.

NEW YORK, NY / ACCESSWIRE / October 12, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI).

About Avenue Therapeutics, Inc.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

For more information, please visit the Company's website: https://www.avenuetx.com

About Aegis Capital Corporation

Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.

For more information about this offering or Investment Banking Services please email Banking@aegiscap.com or call (212) 813-1010.

www.aegiscapcorp.com

Brokerage and investment advisory services are offered through Aegis Capital Corporation, a member of FINRA and SIPC. Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.

SOURCE: Aegis Capital Corporation

View source version on accesswire.com:
https://www.accesswire.com/720075/Aegis-Capital-Corp-Acted-as-Sole-Bookrunner-on-a-12-Million-Underwritten-Public-Offering-for-Avenue-Therapeutics-Inc-NASDAQATXI

FAQ

What is the amount raised in Avenue Therapeutics' recent public offering?

Avenue Therapeutics raised $12 million in its recent underwritten public offering.

Who acted as the bookrunner for the Avenue Therapeutics public offering?

Aegis Capital Corp. acted as the sole bookrunner for Avenue Therapeutics' public offering.

What is the purpose of the funds raised by Avenue Therapeutics?

The funds will be used to support the development of intravenous Tramadol in Phase III clinical trials.

When was the Avenue Therapeutics public offering announced?

The public offering was announced on October 12, 2022.

What product is Avenue Therapeutics developing?

Avenue Therapeutics is developing intravenous Tramadol for post-operative acute pain management.